RSS-Feed abonnieren
DOI: 10.1055/s-0039-1694203
PD-L1 and Ki67 are prognostic in malignant pleural effusion – a retrospective international multicenter study
Publikationsverlauf
Publikationsdatum:
04. September 2019 (online)
Background:
Patients with malignant pleural effusion (MPE) face fatal prognosis and limited treatment options. PD-L1 targeting therapy proved clinical efficacy in various malignancies. Nevertheless data on PD-L1 in MPE is scarce.
Material and method:
A retrospective international multicenter study was performed in Austria (Krems), Germany (Essen) and Turkey (Ankara) including 123 pathological proven MPE patients with available tumor PD-L1 status diagnosed between 2013 and 2018.
Result:
All 123 patients (69 lung cancer, 25 mesothelioma, and 29 extrathoracic malignancies; mean age: 67 ± 12, range: 25 – 91 years, 53 female, 70 male) had malignant cytology and/or pleural biopsy. Median overall survival (OS) after diagnosis was 9.9 months for the whole study cohort. Patients with high (>/= 50%) PD-L1 expression had significant shorter OS (3.9 months) than patients with low (< 50%) PD-L1 (11 months, p = 0.03). Besides PD-L1, we identified Ki67 as novel prognostic biomarker (Ki67 positive tumor cells< 40% OS 11.7 vs. Ki67>/= 40% OS 6.7 months, p < 0.01) in MPE.
Conclusion:
PD-L1 and Ki67 tumor expression were identified as novel prognostic markers in malignant pleural effusion. These findings might help in better estimating prognosis on the one hand and plan further treatment on the other hand.
#